<DOC>
	<DOCNO>NCT02052219</DOCNO>
	<brief_summary>The purpose study compare effect blisibimod plus standard care versus placebo plus standard care alone proportion subject achieve improvement renal disease parameter .</brief_summary>
	<brief_title>BRILLIANT-SC : A Study Efficacy Safety Blisibimod Administration Subjects With IgA Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , IGA</mesh_term>
	<criteria>18 year age old . Biopsyproven IgA nephropathy Proteinuria â‰¥ 2g/24hr equivalent Receiving physiciandirected optimized standard care include ACEI and/or ARB . Estimated glomerular filtration rate ( eGFR ) &gt; 40mL/min/1.73m2 Clinical histologic evidence nonIgArelated glomerulonephritis IgA nephropathy great 50 % glomerulosclerosis cortical scar Meets eGFR criterion Malignancy within past 5 year Known positive HIV and/or positive screen visit hepatitis B , hepatitis C Liver disease Neutropenia Active infection require hospitalization treatment parenteral antibiotic within past 60 day history repeat herpetic viral infection History active tuberculosis history tuberculosis infection Pregnant nursing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2015</verification_date>
	<keyword>Blisibimod</keyword>
	<keyword>IgA nephropathy</keyword>
	<keyword>BAFF</keyword>
	<keyword>BLyS</keyword>
</DOC>